Dechert Advises Royalty Pharma on its Acquisition of Massachusetts General Hospital's Royalty Interest in Entyvio

March 06, 2020

Dechert advised Royalty Pharma on IP-related matters in its acquisition of Massachusetts General Hospital’s royalty interest in Entyvio (vedolizumab), a monoclonal antibody that is used in the treatment of ulcerative colitis and Crohn’s disease, two of the most common forms of inflammatory bowel disease. Entyvio was approved by the U.S. Food & Drug Administration in 2014 and is available in more than 60 countries worldwide.

Royalty Pharma is the industry leader in acquiring pharmaceutical royalties. Massachusetts General Hospital is the original and largest teaching hospital of Harvard Medical School.

The Dechert team advising Royalty Pharma includes intellectual property partners Carl A. Morales, Ph.D., Katherine A. Helm, Ph.D. and Scott A. Warren; intellectual property associates Blaine M. Hackman, Ph.D., and Madeleine White; and patent agent Kurtis M. Anderson, Ph.D.

About Dechert

Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.